All In Biotech

Drug Trial Radar · NCT02164045

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 From an Extended-Release Formulation of BMS-663068 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jul 27, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

38

Actual

Start

Jun 24, 2014

Primary completion

Jul 25, 2014

Study completion Jul 25, 2014

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Jun 16, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The current food effect study is being performed to support a Phase 3 study with BMS 663068. Results from this study will inform whether patients in the upcoming Phase 3 study can be given the flexibility to dose BMS-663068 in the fasted state, if so desired.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

  • BMS-663068Drug

    BMS-663068

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed concentration (Cmax) for BMS-626529 in the presence and absence of foodTime frame: Days 1-4 of Periods 1 and 2
  2. Area under the concentration-time curve in one dosing interval (AUC(TAU)) for BMS-626529 in the presence and absence of foodTime frame: Days 1-4 of Periods 1 and 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.